Clinical trial · Interventional
Vaccination for Children of H&O and Their Parents
Study on Compliance, Safety and Effectivity of Vaccination for Children With Hematologic Malignancies or Solid Tumors and Their Parents
NCT03373656CI-TRIAL-00059894unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to study on compliance, safety and effectivity of vaccination for children with hematologic malignancies or solid tumors and their parents.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hematologic Malignancy | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
| Solid Tumor, Childhood | Childhood Solid Neoplasm | ALIAS | 0.90 |
| Vaccination | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No Vaccination | Other | — | UNRESOLVED |
| Vaccination | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- low antibody titers
- description
- Antibody titers lower than protection level
- interventionNames
- Biological: Vaccination
- type
- OTHER
- label
- high antibody titers
- description
- Antibody titers higher than protection level
- interventionNames
- Other: No Vaccination
Primary outcomes (3)
- measure
- Number of parents of children willing to be vaccinated after receiving relevant knowledge propagation
- timeFrame
- 2 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Children patients(≤18 years) who accepted chemotherapy, hematopoietic stem cell transplantation or splenectomy since our study started. 2. No history of hepatitis B and measles, do not suffer from other diseases that affect immune function and allergic diseases. Exclusion Criteria: 1. Children patients who did not reach clinical remission after treatment, critically ill or eventually died. 2. Patients who used monoclonal antibodies, especially anti-tumor necrosis factors. 3. Intermittent or low-dose chemotherapy or other immunosuppressive drugs users.
References
Publications (0)
Data not yet available
No reference posted for this study.